04 67 20 77 30
contact@sensorion-pharma.com
Sensorion receives European authorization to initiate Phase II clinical trial of SENS-111 to treat acute vertigo
Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo
04 67 20 77 30
